ArticleInternational journal of nanomedicine
Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery.
Article in International journal of nanomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy.Advanced pharmaceutical bulletin · 2024Review
- Hybrid Liposome-MSN System with Co-Delivering Potential Effective Against Multidrug-Resistant Tumor Targets in Mice Model.International journal of nanomedicine · 2024Article
- Stage-specific treatment of colorectal cancer: A microRNA-nanocomposite approach.Journal of pharmaceutical analysis · 2023Review
- Toxicity evaluation of silica nanoparticles for delivery applications.Drug delivery and translational research · 2023Review
- Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses.Antiviral research · 2023Review
- Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes.Investigational new drugs · 2022Article
- Recent Overview of Resveratrol's Beneficial Effects and Its Nano-Delivery Systems.Molecules (Basel, Switzerland) · 2022Review
- Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?Chemical Society reviews · 2022Review
- siRNA delivery using intelligent chitosan-capped mesoporous silica nanoparticles for overcoming multidrug resistance in malignant carcinoma cells.Scientific reports · 2021Article
- Article
- Ultrasound-mediated gene delivery into suspended plant cells using polyethyleneimine-coated mesoporous silica nanoparticles.Ultrasonics sonochemistry · 2021Article
- Calcium Signaling in the Thyroid: Friend and Foe.Cancers · 2021Article
- Facile methodology of nanoemulsion preparation using oily polymer for the delivery of poorly soluble drugs.Drug delivery and translational research · 2020Article
- Tuning Composition of Polymer and Porous Silicon Composite Nanoparticles for Early Endosome Escape of Anti-microRNA Peptide Nucleic Acids.ACS applied materials & interfaces · 2020Article
- Silica-Based Gene Delivery Systems: From Design to Therapeutic Applications.Pharmaceutics · 2020Review
- Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review.Pharmaceutics · 2020Review
- Influence of the Surface Functionalization on the Fate and Performance of Mesoporous Silica Nanoparticles.Nanomaterials (Basel, Switzerland) · 2020Review
- Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules.Pharmaceutics · 2020Review
- Assembly of Multicomponent Nano-Bioconjugates Composed of Mesoporous Silica Nanoparticles, Proteins, and Gold Nanoparticles.ACS omega · 2019Article
- Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.Expert opinion on drug delivery · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small interfering RNA (siRNA) is a highly potent drug in gene-based therapy with the challenge being to deliver it in a sustained manner. The combination of mesoporous silica nanoparticles (MSNs) and polycations in the confined pore space allows for incorporation and controlled release of therapeutic siRNA payloads. We hereby constructed MSNs with expanded mesopores and pore-surface-hyperbranched poly(ethyleneimine) (PEI) tethered with redox-cleavable linkers that could carry a high payload of siRNA (120 mg·g
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.